ELMMB logo
Facebook logo Twitter logo
Menu
MHRA Drug Safety Updates

MHRA Drug Safety Updates

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Drug Safety Update MHRA March-2020-PDF.pdf

Drug Safety Update MHRA March-2020-PDF.pdf
Summary: Esmya - licence suspended: tofacitinib [Xeljanz] - new measures to minimise risk of VTE & of serious and fatal infections: Baricitinib - risk of venous thromboembolism
File Size: 301KB
File Type: application/pdf
Created: 07 April 2020
Last Modified: 09 April 2020